Publication | Open Access

Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC

Immune MicroenvironmentNovel TherapyMedicineImmunologyCell DeathCombination TreatmentImmune Checkpoint InhibitorPharmacotherapyAnti-cancer AgentImmunotherapyPharmacologyOral Chk1 InhibitorTumor Microenvironment